Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 127 results for thyroid* OR hypothyroid* OR Hyperthyroid* OR goiter

  1. Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over (TA1038)

    Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over.

  2. Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over (TA1039)

    Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.

  3. Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]

    In development Reference number: GID-TA11160 Expected publication date: TBC

  4. Teprotumumab for treating thyroid eye disease [ID6432]

    In development Reference number: GID-TA11531 Expected publication date: TBC

  5. Hypothyroidism: register (IND138)

    This indicator covers the contractor establishing and maintaining a register of patients with hypothyroidism who are currently treated with levothyroxine. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM99.

  6. Diabetes: thyroid disease screening (children T1DM) (IND312)

    This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have been screened for thyroid disease in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  7. Learning disabilities: annual TSH test (IND79)

    This indicator covers the percentage of patients on the learning disability register with Down's Syndrome aged 18 and over who have a record of blood TSH in the previous 15 months (excluding those who are on the thyroid disease register). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM04

  8. Dementia: target organ damage (all patients) (IND118)

    This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72

  9. What is the clinical and cost effectiveness of dosimetry-guided radioactive iodine strategies for hyperthyroidism?

    effectiveness of dosimetry-guided radioactive iodine strategies for hyperthyroidism? Any explanatory notes(if applicable) Why the...

  10. What is the clinical and cost effectiveness of selenium for people with subclinical hypothyroidism?

    subclinical hypothyroidism? Any explanatory notes(if applicable) Source guidance details Comes from guidance Thyroid...

  11. What is the clinical and cost effectiveness of iodine for people with subclinical hypothyroidism?

    subclinical hypothyroidism? Any explanatory notes(if applicable) Source guidance details Comes from guidance Thyroid...

  12. What is the clinical and cost effectiveness of levothyroxine for people under 65 with symptomatic subclinical hypothyroidism?

    subclinical hypothyroidism? Any explanatory notes(if applicable) Source guidance details Comes from guidance Thyroid...

  13. What is the long-term clinical and cost effectiveness, including safety, of radioactive iodine for hyperthyroidism?

    and cost effectiveness, including safety, of radioactive iodine for hyperthyroidism? Any explanatory notes(if applicable) Why the...

  14. What is the clinical and cost effectiveness of treatment (antithyroid drugs or radioactive iodine) for improving long-term health outcomes for people with subclinical hyperthyroidism?

    for improving long-term health outcomes for people with subclinical hyperthyroidism? Any explanatory notes(if applicable) Why the...